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Abstract 
Background: Histone posttranslational modifications (PTMs) function to regulate chromatin structure and function 
in part through the recruitment of effector proteins that harbor specialized “reader” domains. Despite efforts to eluci-
date reader domain–PTM interactions, the influence of neighboring PTMs and the target specificity of many reader 
domains is still unclear. The aim of this study was to use a high-throughput histone peptide microarray platform to 
interrogate 83 known and putative histone reader domains from the chromo and Tudor domain families to identify 
their interactions and characterize the influence of neighboring PTMs on these interactions.
Results: Nearly a quarter of the chromo and Tudor domains screened showed interactions with histone PTMs by 
peptide microarray, revealing known and several novel methyllysine interactions. Specifically, we found that the CBX/
HP1 chromodomains that recognize H3K9me also recognize H3K23me2/3—a poorly understood histone PTM. We 
also observed that, in addition to their interaction with H3K4me3, Tudor domains of the Spindlin family also recog-
nized H4K20me3—a previously uncharacterized interaction. Several Tudor domains also showed novel interactions 
with H3K4me as well.
Conclusions: These results provide an important resource for the epigenetics and chromatin community on the 
interactions of many human chromo and Tudor domains. They also provide the basis for additional studies into the 
functional significance of the novel interactions that were discovered.
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Background
Dynamic regulation of chromatin structure is linked to 
the regulation of all DNA-templated processes includ-
ing gene expression [1, 2]. Histone posttranslational 
modifications (PTMs) represent one of the major mech-
anisms for regulating the chromatin landscape [3, 4]. 
Histone PTMs include acetylation, phosphorylation, 
and methylation among many others, and these differ-
ent chemical signatures exert their effects on chromatin 
structure both in a type- and site-specific manner [5–8]. 
One of the primary mechanisms by which histone PTMs 
alter chromatin structure is via the recruitment of effec-
tor proteins that contain specialized “reader” domains 
that specifically recognize different histone PTMs [5, 9, 
10]. These effectors may be transcription factors or addi-
tional chromatin-modifying machinery, and often their 
functions define the downstream consequences associ-
ated with distinct histone PTMs [10–12].
Histone lysine (K) methylation represents one of the 
major histone PTMs and over 170 methyllysine readers 
are thought to exist in humans [13]. Lysine methylation 
can take the form of mono-, di-, or trimethylation, and 
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often each state is associated with distinct genomic loca-
tions and unique functional outcomes [14–16]. The major 
sites of K-methylation on histone H3 are K4, K9, K27, 
K36, and K79, while K20 is the predominant K-meth-
ylation site on histone H4 [14, 15, 17, 18]. Interestingly, 
histone K-methylation is associated with both transcrip-
tionally permissive and transcriptionally repressive states 
of chromatin, dependent on the site and degree of meth-
ylation. For instance, monomethylation of histone H4 at 
Lys 20 (H4K20me1) is associated with actively transcribed 
regions, while trimethylation of H3K9 (H3K9me3) is asso-
ciated with transcriptionally silent chromatin [19–23]. 
This suggests that methyllysine readers are specific both 
for the degree of methylation and for the sequence context 
surrounding the methylated residue. However, some sites 
of K-methylation, such as H3K9 and H3K27, share a com-
mon ARKS sequence context, suggesting that some reader 
domains may recognize multiple sites and may require 
additional factors for specificity. Indeed, many chromatin 
modifiers and transcriptional machinery contain multiple 
reader domains that simultaneously engage multiple his-
tone PTMs in a form of “cross-talk” [24]. Furthermore, the 
residues flanking methyllysine hotspots are often subject 
to PTMs that may permit or impede binding of methyl-
lysine readers. For example, phosphorylation of serine 10 
of H3 (H3S10p) inhibits binding of H3K9me3-specific 
reader domains, and cis-histone tail H3K9me3/S10p has 
been observed in cells [25, 26]. Similarly, phosphorylation 
of H3T3, and to a lesser degree H3T6, impedes binding of 
H3K4me3-specific reader domains, while symmetrical or 
asymmetrical dimethylation of H3R2 (H3R2me2s/a) has 
little effect on certain domain interactions [27], but can 
block or promote others [28–30].
Known methyllysine reader domains include the plant 
homeodomain (PHD) fingers, the bromo-adjacent homol-
ogy (BAH) domains, and the “Royal family” domains [17, 
31, 32]. The Royal family of methyllysine readers is con-
served throughout eukaryotic evolution and includes the 
chromo-, Tudor-, PWWP-, and malignant brain tumor 
(MBT)-structural domains [33]. Members of this fam-
ily are known to interact with multiple different sites of 
K-methylation on histones and other proteins. Structural 
and mechanistic studies of the heterochromatin protein 1 
(HP1) chromodomain provided some of the first insights 
into the molecular mechanism of methyllysine recogni-
tion. A co-crystal structure of the HP1 chromodomain 
bound to an H3K9me3 peptide revealed that a hydropho-
bic region composed of three conserved aromatic resi-
dues stabilizes the interaction with the methyllysine side 
chain via cation–π and hydrophobic interactions [34]. 
Additional structure–function studies showed that this 
“aromatic cage” is a general feature of many methyllysine 
readers even outside the Royal family [35]. However, the 
site- and methyl-state specificity for many members of the 
Royal family is unclear. Moreover, several of the known 
members of this family are uncharacterized for their 
interactions with histone PTMs.
While multiple histone K-methylation sites are known, 
advances in mass spectrometry have increased the num-
ber of known sites [36]. However, it is unclear whether the 
current repertoire of known methyllysine readers, includ-
ing members of the Royal family, also interacts with these 
newly identified sites or whether there are distinct read-
ers for each site. In this investigation, we set out to use a 
high-throughput proteomics approach utilizing custom-
ized histone peptide microarrays to survey a large number 
of human chromo and Tudor domains for their binding to 
various histone PTMs. We identified several new histone 
PTM–reader domain interactions for previously charac-
terized readers and identified a subset of H3K9-methyl 
readers that are also capable of reading H3K23 methyla-
tion—a newly identified yet poorly understood histone 
PTM. The results of our survey will facilitate future stud-
ies characterizing the structure–function relationships 
and biological consequences of these interactions.
Results
We selected 31 chromodomains and 39 Tudor or Tudor-
like domains to screen using our histone peptide microar-
ray platform. Several additional protein reader domains 
were also screened, for a total of 83 proteins screened by 
peptide microarray (Additional file 1: Table S1). Our pep-
tide microarray platform consists of nearly 300 biotinylated 
histone peptides harboring unique PTMs at one or more 
residues immobilized to a streptavidin-coated glass surface 
(Additional file 2: Table S2) [37, 38]. The arrays were probed 
in duplicate with purified GST-tagged protein domains, 
and binding to specific PTMs was detected using fluores-
cently labeled antibodies (see Methods). Twenty-two of the 
83 selected domains showed positive hits with one or more 
histone peptides on the arrays. As shown in Table 1, many 
of the known binding targets for these protein domains 
were detected, as well as several novel interactions. Based 
on these observations, we focused on further character-
izing (1) the novel interaction between Spindlin1 (SPIN1) 
triple Tudor domain and H4K20me3 and (2) the interaction 
between several chromodomains and H3K23me2/3.
SPIN1 is a transcriptional coactivator that contains a tri-
ple Tudor domain known to interact with H3K4me3—a 
mark associated with actively transcribed genes [39–41]. 
As expected, the SPIN1 triple Tudor and several other 
known H3K4me-binding domains, including the PHD 
domain of Taf3 and the tandem Tudor domains of JMJD2A 
and SGF29, strongly interacted with H3K4me2/3 (Fig. 1a; 
Additional file 3: Figure S1, and Additional file 4: Figure S2). 
Interestingly, phosphorylation of H3T3 inhibited binding of 
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SGF29 tandem Tudor and Taf3 PHD, but did not interfere 
with SPIN1 triple Tudor or JMJD2A tandem Tudor interac-
tion with H3K4me3. In contrast, all of the H3K4me3 reader 
domains, including CHD1 chromodomain, accommodated 
H3K4me3 with neighboring H3R2me2a. Furthermore, the 
chromodomains of CHD7 and CHD9 showed robust inter-
action with both the unmodified H3 and H4N-terminal 
tails, while the chromodomain of CHD1 showed interac-
tion with the H4 tail but not with the unmodified H3 tail 
(Fig. 1a; Additional file 5: Figure S3, Additional file 6: Figure 
S4, and Additional file 7: Figure S5). In addition, the tan-
dem Tudor of 53BP1 preferentially bound H4K20me1/2 as 
previously described (Fig. 1a) [42].
Surprisingly, the SPIN1 triple Tudor domain also 
bound H4K20me3-containing peptides (Fig.  1b, c). This 
novel interaction was highly reproducible on the peptide 
microarrays and was confirmed by in-solution peptide 
pull-down assays (Additional file 3: Figure S1A and S1B). 
We further validated the specificity of the interaction 
using peptide pull-down experiments with full-length 
SPIN1 protein and tested the possibility that other Spin-
dlin family members (SPIN2B, SPIN3, and SPIN4) inter-
act with H4K20me3. Indeed, full-length SPIN1 protein 
preferentially bound H4K20me3 and showed less inter-
action with mono- or dimethylated H4K20 (Fig.  1d). 
Like SPIN1, full-length SPIN2B, SPIN3, and SPIN4 also 
showed preference for trimethylated H3K4 and H4K20 
(Fig.  1d). In order to test whether SPIN1 family mem-
bers interact with H4K20me3 peptides in the context of 
the cellular milieu, we transfected 293T cells with con-
structs containing individual SPIN1 family proteins fused 
with green fluorescent protein (GFP) and performed 
peptide pull-down experiments with whole cell lysates. 
The results from these assays mimic the results obtained 
using purified proteins, further suggesting that SPIN1 
family proteins preferentially interact with H3K4me3 
and H4K20me3 in cells (Fig. 1e; Additional file 3: Figure 
S1C). Notably, while we were unable to purify SPIN2A to 
high enough quality for use in in vitro pull-down assays 
using purified proteins, we were able to assess SPIN2A 
binding to H3K4me3/H4K20me3 peptides using lysates 
from transfected cells. These results show that, like other 
SPIN1 family members, SPIN2A is capable of interacting 
with both H3K4me3 and H4K20me3 (Fig. 1e).
Previous crystallographic analysis of the interaction 
between SPIN1 triple Tudor and H3K4me3 revealed 
Table 1 Summary of reader domain interactions identified via histone peptide microarrays
Italics, validated by peptide pull-down assays
a Novel interactions
Protein Domain Top array hits Known interactions References
HP1β/CBX1 Chromo H3K9me1/2/3, H3K23me1/2/3 H3K9me1/2/3, H3K23me1/2/3 [21, 22, 46, 52]
HP1γ/CBX3 Chromo H3K9me1/2/3, H3K23me3a H3K9me2/3 [21, 22, 52, 74]
HP1α/CBX5 Chromo H3K9me1/2/3, H3K23me3a H3K9me1/2/3 [21, 48, 52]
CDYL1b Chromo H3K9me1/2/3, H3K27me2/3 H3K9me1/2/3, H3K27me1/2/3 [75]
CDYL2 Chromo H3K9me2/3, H3K27me3 H3K9me1/2/3, H3K27me1/2/3 [76]
CHD1 Chromo (2) H3K4me2/3 H3K4me3 [54, 55]
CHD7 Chromo (2) H4me0 H3K4me1/2/3 [56]
CHD9 Chromo (2) H4me0
MPP8 Chromo H3K9me1/2/3, H3K23me2/3 H3K9me1/2/3, H3K23me1/2/3 [46, 77, 78]
53BP1 Tudor (2) H3K4me2, H3K18me2a, H3K36me2a, H4K20me1/2 H3K4me2, H4K20me1/2 [42, 52]
JMJD2A Tudor (2) H3K4me2/3, H3K18me3a, H3K9me3, H4K20me2/3 H3K4me3, H4K20me2/3 [51, 52]
PHF20 Tudor (2) H3K9me2/3, H4K8me1 H3K9me2, H3K27me2, H3K36me2 [35]
UHRF1 Tudor-like H3K9me2/3 H3K9me2/3 [79, 80]
PHF1 Tudor H3K36me3 H3K36me2/3 [81–84]
SGF29 Double Tudor H3K4me3 H3K4me1/2/3 [85]
SPIN1 Triple Tudor H3K4me2/3, H3K18me3, H4K20me3a H3K4me2/3 [40]
TDRD2 Tudor (extended) H3K4me3
TDRD3 Tudor H3R2me2a, H3R8me2a pan-Rme2a [53]
GLP ANK H3K9me1/2 H3K9me1/2 [86]
ING2 PHD H3K4me2/3 H3K4me2/3 [87, 88]
TAF3 PHD H3K4me2/3 H3K4me2/3 [89]
L3MBTL1 MBT (3) H3K4me2, H3K9me2, H4K8me1 H3K4me1/2, H3K9me1/2, H3K27me1/2, 
H4K20me1/2
[90–92]
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Fig. 1 SPIN1 triple Tudor domain interacts with H4K20me3 as well as H3K4me3. a Heat map showing the relative binding detected for each of the 
indicated domains on the peptide microarray platform. Data represent the average of two independent arrays relative to the most intense binding 
signal within the indicated set of peptides. b Scatter plot of the relative binding of SPIN1 triple Tudor domain from two independent peptide arrays. 
H3K4me3-containing peptides are shown in red and H4K20me3-containing peptides are shown in blue. All other peptides are shown in black.  
c Representative picture of a section of the peptide microarray for SPIN1 triple Tudor domain. The left panel shows both the green (peptide) and red 
(protein binding) fluorescent channels, while the right panel depicts only the red fluorescence channel for clarity. Positive antibody controls are out-
lined in white and the positive interaction with the H4K20me3 peptide is outlined in yellow. Full array images are shown in Additional file 3: Figure 
S1. d Western blot results of peptide pull-down experiments with purified full-length Spindlin family members. The input is shown in Lane 1 and the 
corresponding bound fraction is shown in Lanes 2–8. e Western blot results of peptide pull-down experiments with whole cell lysates derived from 
transiently transfected HEK 293T cells (GFP-SPIN1, 2A, 2B, 3 and 4). f Western blot results of peptide pull-down experiments with purified SPIN1 wild 
type (SPIN1WT) or aromatic cage mutant in the second Tudor domain (SPIN1Y170A) demonstrating a loss of H3K4me3 and H4K20me3 in the mutant
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an aromatic cage in the second Tudor domain of the 
SPIN1 triple Tudor that coordinates the trimethylated 
lysine residue [41]. In order to determine whether the 
interaction with H4K20me3 occurs through the same 
aromatic cage, we generated a tyrosine 170 to alanine 
(Y170A) mutation in the aromatic cage of SPIN1 and 
tested the interaction with H4K20me3 using peptide 
pull-down analyses. As shown in Fig. 1f, the Y170A vari-
ant showed minimal interaction with both H3K4me3 
and H4K20me3. The SPIN1 Y170A mutation was pre-
viously shown to disrupt H3K4me3 binding [43]; thus, 
our results suggest that H4K20me3 is coordinated in the 
same aromatic pocket. Additional structural and func-
tional studies show that H3R8me2a enhances the bind-
ing of SPIN1 to H3K4me3-containing peptides [43]. The 
methylated Arg8 side chain is coordinated in a hydropho-
bic pocket in the first Tudor domain of SPIN1, while the 
H3K4me3 residue is coordinated in the second Tudor 
domain [43]. In order to confirm that the Y170A mutant 
specifically disrupts the second Tudor domain, we tested 
the interaction of SPIN1 with a peptide containing the 
double H3K4me3/H3R8me2a modification. Both wild-
type SPIN1 and the Y170A variant showed enhanced 
interaction with the H3K4me3/H3R8me2a peptide 
compared to the H3K4me3 peptide, suggesting specific 
disruption of the second Tudor domain in the Y170A 
variant (Fig. 1f ). Together, these results indicate that the 
second Tudor domain of SPIN1 can bind both H3K4me3 
and H4K20me3 in a mutually exclusive manner.
The second novel interaction we detected occurred 
between several chromodomains and H3K23me pep-
tides. As shown in Fig. 2a, the chromodomains of CBX1, 
CBX3, CBX5, CDYL2, and MPP8 showed strong interac-
tion with H3K9me3, even in the context of neighboring 
arginine 8 asymmetrical or symmetrical dimethylation. 
In all cases, H3S10phos inhibited the interaction with 
H3K9me3 and there was a clear preference for H3K9me3 
over H3K27me3. In addition to the well-characterized 
interactions with H3K9me3, we also observed bind-
ing to H3K23me-containing peptides. To validate these 
interactions, we performed peptide pull-down experi-
ments with H3K9, H3K23, and K3K27 peptides with 
varied degrees of methylation. As shown in Fig.  2b, we 
observed that CBX1, CBX3, CBX5, and MPP8 chromo-
domains interacted with H3K9me1/2/3 peptides and 
H3K23me2/3 peptides, but showed minimal interactions 
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Fig. 2 Chromodomains interact with H3K23me2/3 in addition to H3K9me1/2/3. a Heat map showing the relative binding detected for each of the 
indicated domains on the peptide microarray platform. Data represent the average of two independent arrays relative to the most intense binding 
signal within the indicated set of peptides. b Western blot results of peptide pull-downs performed with the indicated GST-tagged domain and 
histone peptide. The input is shown in Lane 1 and the bound fraction is shown in Lanes 2–13
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with H3K27me1/2/3 peptides. CDYL1B and CDYL2 
showed preference for H3K9me2/3 peptides and very 
weak interactions with H3K23me peptides and H3K27me 
peptides. These results suggest that members of the CBX 
family of H3K9me3 reader domains, which have high 
selectivity for H3K9 over a very similar sequence motif at 
H3K27 (i.e., ARKS), are robust readers of H3K23 meth-
ylation, thus implicating H3K23 methylation, along with 
H3K9me, in the silencing functions of these domains.
Discussion
The aim of this study was to create a valuable resource 
of chromo and Tudor reader domains for their interac-
tions and cross-talk between histone PTMs. This work 
was facilitated by the use of a high-throughput approach 
employing peptide microarrays containing nearly 300 
biotinylated histone peptides harboring up to five PTMs 
on each peptide (Additional file 2: Table S2). While sev-
eral other histone peptide microarray platforms have 
been described [44–47], there are several notable fea-
tures of our peptide array platform that aided the current 
study. These include highly purified peptides of lengths 
greater than 20 amino acids, along with each peptide 
being spotted multiple times by multiple pins to provide 
a robust number of data points that gave us high confi-
dence in the interactions (and changes in these interac-
tions by neighboring PTMs) that we observed.
Our survey of histone reader domains is one of the larg-
est screens for histone PTM–reader domain interactions 
to date. We expressed and purified 83 protein domains, 
including 31 chromodomains and 39 Tudor or Tudor-like 
domains. We screened each domain in duplicate, and 22 
domains exhibited consistent, reproducible binding to 
histone peptides on our arrays. The majority of the pro-
tein domains we tested, however, did not exhibit bind-
ing to histone peptides (see full list of domains screened 
in Additional file 1: Table S1). There are several possible 
explanations for this. First, our previous observations 
suggest that binding affinities weaker than approximately 
30 µM are typically beyond the limit of detection for this 
platform [37]. It is notable that many reader domains 
exhibit weak interactions with histone peptides, which 
may account for a substantial number of negatives in our 
screen. For example, the chromodomain of CBX2 has 
been shown to bind H3K9me3 and H3K27me2 peptides 
with a binding affinity of ~40 µM via fluorescence polari-
zation [48], which would explain why this chromodo-
main failed to show PTM interactions as compared to the 
other CBX domains. Second, we screened several protein 
domains with unknown histone PTM binding targets. For 
example, the Tudor domains of TDRD1 and TDRD2 are 
known to interact with methylated Piwi proteins [49, 50], 
but there are no known methyl-histone binding targets 
known to date. Similarly, TDRD4, TDRD9, and several 
other TDRD family members have no known methyl-his-
tone binding targets, and it is possible that these Tudor 
domains do not interact with histones. Third, the recom-
binant protein domains we expressed and purified may 
require additional sequences from their respective pro-
teins that are needed for histone PTM binding and are 
not present in the domains we designed. Indeed, the sin-
gle Tudor domain of PHF20 was negative on our arrays, 
but the tandem Tudor domain interacted with H3K9me2, 
as previously shown [35]. In addition, the domains we 
purified may require interaction with other proteins in 
order to bind histones. Finally, it is possible that the con-
ditions we used in this high-throughput approach were 
not amenable to binding for some proteins.
Of the 31 Tudor or Tudor-like domains we screened, 
several known interactions were detected on our arrays 
(Table  1). Both 53BP1 and JMJD2A tandem Tudor 
domains showed binding to H3K4me and H4K20me pep-
tides as previously shown [42, 51, 52]. Some novel inter-
actions were also detected on the peptide arrays, such as 
binding to H3K18me, but further experiments need to 
be performed to validate these findings. TDRD3 Tudor 
domain specifically recognized asymmetrically dimethyl-
ated peptides, as previously shown [53], but our results 
suggest that this Tudor domain has broad affinity for 
Rme2a-containing peptide (Additional file  8: Figure S6 
and Table  1). Of the 39 chromodomains we surveyed, 
nearly 20% interacted with modified histone peptides. 
Many of these interactions are well characterized, such as 
binding to H3K9me peptides by the CBX family of pro-
teins [21, 22, 52]. We also observed interaction between 
CHD1 chromodomain and H3K4me3 as previously 
described [54, 55]. Intriguingly, the chromodomains of 
CHD1, CHD7, and CHD9 all showed interactions with 
unmodified histone H4 peptide, and CHD7 and CHD9 
also interacted with unmodified histone H3 peptide 
(Additional file  5: Figure S3, Additional file  6: Figure 
S4, Additional file  5: Figure S5, and Table  1). Although 
CHD9 chromodomains have not been shown to bind 
methylated histones, H3K4me1/2/3 peptides were shown 
to competitively disrupt histone interactions with puri-
fied histones, which is in agreement with the idea that 
the H3N terminus can bind the chromodomain of CHD9 
[56]. It should be noted that unmodified histone H3 pep-
tides were not tested in these experiments, but based on 
our findings, we speculate the K4 unmodified peptide 
would have also competed CHD9 chromodomain inter-
action given our results show general H3 binding without 
preference to the H3K4 methyl state.
Due to the large scope of this microarray screen, we 
focused on validating only a subset of interactions by 
peptide pull-down experiments. The two most significant 
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and novel interactions we uncovered were with H3K23me 
and H4K20me peptides. First, we observed that several 
chromodomains interacted with H3K23me, in addition 
to the known H3K9me targets. MPP8 and CBX1 chro-
modomains have been shown to interact with H3K23me 
peptides at low micromolar binding affinities [46]. We 
confirmed these results in our screen and observed that 
additional chromodomains, CBX3 and CBX5, also inter-
act with H3K23me2/3. In our study, we observed prefer-
ential binding to di- and trimethylated states of H3K23. 
All three methylation states of H3K23 have been detected 
in cells [46], and a recent report suggests that H3K23me3 
colocalizes with H3K27me3 and plays a role in protecting 
heterochromatin from double-strand DNA breaks dur-
ing meiosis [57]. It is possible that the dual modification 
may provide an even better binding substrate for these 
chromodomains, which will be interesting to explore 
in future biological studies. In contrast, the CDY family 
members that exhibited binding on our arrays (CDYL1B 
and CDYL2) showed preference for H3K9me3 and did 
not interact with H3K23me peptides. Notably, a recent 
report suggested that H3K23 methylation regulates levels 
of H3K36 methylation by recruiting the H3K36 demeth-
ylase, KDM4B, via its double Tudor domain [58]. How-
ever, none of the Tudor domains surveyed here showed 
interaction with H3K23 methylation.
We also focused on the novel interaction between the 
SPIN1 Tandem Tudor domain and H4K20me2/3, which 
we validated by peptide pull-down experiments and dem-
onstrated with other Spindlin family members (Fig. 1d). 
In the context of full-length protein, SPIN1 shows 
remarkable preference for trimethylation at H3K4 and 
H4K20. SPIN2B and SPIN3 show similar selectivity, while 
SPIN4 seems to accommodate both di- and trimethylated 
H4K20me3. SPIN1 is composed of three homologous 
Tudor domains denoted I, II, and III [39]. The second 
Tudor domain (II) is composed of the aromatic residues 
Phe 141, Trp 151, Tyr 170, and Tyr 177, which together 
form the aromatic cage that coordinates the methyl lysine 
[41]. Our observation that the Tyr170Ala variant loses 
interaction with both H3K4me3 and H4K20me3 suggests 
that domain II is responsible for recognizing both modi-
fications. This further suggests that SPIN1 interacts with 
H3K4me3 and H4K20me3 at different times and/or dif-
ferent genomic locations, possibly under different cellular 
conditions.
Lysine 20 is the predominant methylation site on H4, 
and this modification is important for development in 
higher eukaryotes (reviewed in [59]). H4K20 methyla-
tion is associated with regulating transcription, the DNA 
damage response, and cell cycle progression [59]. Mul-
tiple H4K20 methyl readers have been described, and 
many of them contain a Tudor or Tandem Tudor domain 
like SPIN1 [59]. These readers of H4K20me are thought 
to mediate the cellular roles ascribed to H4K20 methyla-
tion. For instance, the Tandem Tudor domain of 53BP1 is 
required for localization of 53BP1 to sites of DNA dam-
age where it acts as a mediator of DNA damage signal-
ing and repair [42, 60, 61]. Interestingly, different levels of 
H4K20 methylation are associated with different effects 
on transcription. For instance, H4K20me1 is associated 
with active transcriptional states of chromatin, while 
H4K20me3 is associated with transcriptionally silent 
chromatin regions [19, 62, 63]. Our data suggest that 
SPIN1 and other Spindlin family members are capable of 
recognizing both a transcriptional activation modifica-
tion (i.e., H3K4me3) and a transcriptional silencing mod-
ification (i.e., H4K20me3). This result is, to the best of 
our knowledge, the first example of a reader domain that 
can read both activating and deactivating histone PTMs.
As H4K20 methylation is important in several cellular 
processes, aberrant H4K20 methylation is observed in 
several cancers and mutations in H4K20 methyl reader 
domains have been described in human developmental 
disorders [64–66]. Furthermore, SPIN1 is overexpressed 
in several varieties of malignant tumors and upregula-
tion of SPIN1 is known to increase cellular proliferation 
and cause chromosomal instability and abnormal mito-
sis [67–71]. The interaction of SPIN1 with H4K20me2/3 
may play a part in mediating some of the roles associated 
with H4K20 methylation, but additional in  vivo studies 
are needed to determine the biological importance of 
this interaction. Chemical probes that inhibit the interac-
tion of SPIN1 with H3K4me3 peptides in vitro have been 
described [72, 73]. Our work suggests that these probes 
could also be useful tools for characterizing the SPIN1-
H4K20me interaction in vivo.
Conclusions
This high-throughput screen aimed to determine the 
histone PTM binding targets of known and putative 
chromo and Tudor reader domains to create a valuable 
resource for future studies of these domains. Our sur-
vey encompassed the majority of human chromo and 
Tudor domains, and uncovered known and unknown 
histone PTM interactions. Of the many hits we observed, 
we focused on two novel interactions: (1) chromodo-
main recognition of H3K23me and (2) recognition of 
H4K20me3 by the Spindlin family of proteins. Future 
work will be needed to uncover the importance of these 
interactions in vivo.
Methods
Protein expression and purification
Codon optimized constructs were synthesized and 
cloned into pGEX-4T-1 expression vectors (GE 
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Healthcare) by Biomatik. Proteins were expressed in sol-
uBL21 (DE3) (Amsbio) grown in Terrific Broth II media 
(MP Biomedicals). After culturing at 37 °C until an OD600 
of ~0.6, cells were chilled for 30 min at 4 °C before induc-
tion with 1 mM IPTG for 20 h at 16 °C. Cells were har-
vested by centrifugation and pellets were flash frozen 
in liquid nitrogen. For purification, thawed cell pellets 
were resuspended in binding buffer (50 mM Tris pH 7.5, 
250 mM NaCl, 4 mM DTT, 10% glycerol) supplemented 
with a protease inhibitor cocktail (Roche), 0.1 mM phe-
nylmethane sulfonyl fluoride (PMSF), 0.5 mg/ml chicken 
egg lysozyme (Sigma), and 0.2% (v/v) Triton X-100. After 
incubation on ice for 45 min, cells were lysed by sonica-
tion and clarified by centrifugation. Lysates were incu-
bated with glutathione agarose (Pierce) and then washed 
with 10 bed volumes of binding buffer. Bound protein was 
eluted with elution buffer (50 mM Tris pH 8.0, 250 mM 
NaCl, 4  mM DTT, 10% glycerol, 10  mM reduced glu-
tathione) and then dialyzed against 3  l of binding buffer 
at 4 °C. Samples were concentrated by centrifugation and 
protein concentration and purity were determined by 
Bradford Assay (BioRad) and SDS-PAGE, respectively.
Peptide microarrays
The peptide microarrays were generated and assayed 
as described previously [37, 38], except that the arrays 
contained four triplicate spots of each peptide. Briefly, 
GST-tagged proteins were diluted to 0.5–2 μM in phos-
phate-buffered saline (PBS) supplemented with 0.1% 
(v/v) Tween-20 (PBST) and 5% (w/v) bovine serum albu-
min (BSA, EMD Millipore Omnipure Fraction V) and 
incubated with peptide microarrays overnight at 4  °C. 
Arrays were washed three times with PBS and then 
probed with an anti-GST antibody (EpiCypher Inc.; 
Cat. No. 13-0022) diluted to 1:1000 in PBST + 5% BSA. 
Arrays were washed again 3× with PBS and then probed 
with an Alexa Fluor 647-conjugated anti-rabbit antibody 
at 1:10,000 (ThermoFisher). Arrays were imaged using a 
Typhoon Scanner and protein binding was determined 
as previously described [37, 38]. The average signal inten-
sity for each peptide was normalized to the most intense 
binding within an array, and normalized binding was 
averaged for at least two independent replicates for each 
protein. Heat maps of relative binding were generated 
using JavaTree View (version 1.16r4) after normalizing 
the relative binding within the subset of peptides selected 
for the heat map.
In‑solution peptide pull‑down assays
For pull-down experiments using purified proteins, a 
total of 50  pmol of GST-tagged protein was incubated 
with 500  pmols of biotinylated histone peptide for 1  h 
at 4  °C in peptide binding buffer (50  mM Tris pH 8.0, 
300  mM NaCl, 0.1% NP-40). Following incubation, the 
protein–peptide mixture was incubated with streptavi-
din-coated magnetic beads (Pierce) and pre-equilibrated 
with peptide binding buffer, for 1 additional hour at 4 °C. 
The beads were washed three times with peptide bind-
ing buffer, and bound complexes were eluted with 1x SDS 
loading buffer, then resolved via SDS-PAGE and trans-
ferred to a PVDF membrane. The membrane was probed 
with an anti-GST antibody (EpiCypher Inc.; Cat. No. 
13-0022) diluted 1:4000 in PBST supplemented with 5% 
(w/v) BSA (Sigma).
For pull-down experiments using cell lysates, HEK 
293T cells were transiently transfected with GFP-SPIN1, 
2A, 2B, 3, and 4 using polyethylenimine according to 
manufacturer’s instructions. Cells were lysed in ice-cold 
mild lysis buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 
0.1% NP-40, 5 mM EDTA, 5 mM EGTA, 15 mM MgCl2) 
containing protease inhibitor cocktail (Roche). Thirty 
microliter of streptavidin agarose beads (Millipore) was 
pre-washed with binding buffer and incubated with 10 µg 
of biotinylated histone peptides for 2  h with rocking at 
4 °C. The beads were then washed three times with 500 μl 
binding buffer to remove unbound peptide. The peptide–
streptavidin agarose mix was then incubated overnight 
with the whole cell lysates and rocked at 4 °C. After three 
washes with 500 μl binding buffer, 30 μl of 2× SDS load-
ing buffer was added to the beads and boiled. The sam-
ples were subjected to SDS-PAGE and Western blotting 
analysis using polyclonal GFP antibody (Santa Cruz Bio-
tech, 1:3000).
Additional files
Additional file 1: Table S1. Protein domains screened by histone 
peptide microarray.
Additional file 2: Table S2. Histone peptide library used for peptide 
microarrays.
Additional file 3: Figure S1. SPIN1 Tudor domain interaction with 
H3K4me3 and H4K20me3. A) Representative array images of SPIN1 Tudor 
domain showing peptide binding indicated in red (right panel). The 
peptide tracer is shown in green (left panel). Positive antibody controls 
are outlined in white. B) Western blot results of peptide pull-down experi-
ments with SPIN1 tandem Tudor domain. The input is shown in Lane 1 
and the corresponding bound fraction is shown in Lanes 2–8. C) Western 
blot results of peptide pull-down experiments with whole cell lysates 
derived from transiently transfected HEK 293T cells (GFP-SPIN1, 2A, 2B, 3 
and 4).
Additional file 4: Figure S2. Peptide microarray data for SGF29 and Taf3. 
Representative array images of A) SGF29 double Tudor domain and Taf3 
PHD domain showing peptide binding indicated in red (right panel). The 
peptide tracer is shown in green (left panel). Positive antibody controls are 
outlined in white.
Additional file 5: Figure S3. CHD1 chromodomain histone peptide 
microarray. A) Representative array images of CHD1 chromodomain 
showing peptide binding indicated in red (right panel). The peptide tracer 
is shown in green (left panel). Positive antibody controls are outlined in 
white. B) Scatter plot of the relative binding of CHD1 chromodomain from 
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